IL-23 inhibition for the treatment of psoriatic arthritis

References

• Tillett W, Charlton R, Nightingale A, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK clinical practice research datalink with a hospital-based cohort. Rheumatology. 2017;56(12):2109–2113.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 2005/10/01;53(4):573.e1–573.e13.
   Web of Science ®Google Scholar
• Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–740.
   PubMed Web of Science ®Google Scholar
• Madland TM, Apalset EM, Johannessen AE, et al. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol. 2005;32(10):1918–1922.
   PubMed Web of Science ®Google Scholar
• Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994 Sep;33(9):834–839.
   PubMedGoogle Scholar
• Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009 2009/02/01;5(2):83–91.
   PubMedGoogle Scholar
• Ho PYPC, Barton A, Worthington J, et al. HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis. 2007;66(6):807–811.
   PubMed Web of Science ®Google Scholar
• Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2016;75(1):155–162.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2012;71(1):50–55.
   PubMed Web of Science ®Google Scholar
• Breban M, Beaufrère M, Glatigny S. The microbiome in spondyloarthritis. Best Pract Res Clin Rheumatol. 2019 2019/12/01/;33(6):101495.
   PubMed Web of Science ®Google Scholar
• Soltani-Arabshahi R, Wong B, Feng B-J, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721–726.
   PubMedGoogle Scholar
• Pattison E, Harrison BJ, Griffiths CEM, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case–control study. Ann Rheum Dis. 2008;67(5):672–676.
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Tessmer M, Chao CC, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011 Jul 15;187(2):951–959.
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136):2273–2284.
   PubMed Web of Science ®Google Scholar
• Alberts BJA, Lewis J. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.
   Google Scholar
• Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76(10):e36–e36.
   PubMed Web of Science ®Google Scholar
• Wedebye Schmidt EG, Larsen HL, Kristensen NN, et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013;19(8):1567–1576.
   PubMed Web of Science ®Google Scholar
• Wang J, Bhatia A, Krugliak Cleveland N, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J. 2018;5:e56.
   PubMed Web of Science ®Google Scholar
• Fieldhouse KA, Ukaibe S, Crowley EL, et al. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. In: Drugs Context. 2020. p. 9.
   Google Scholar
• Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2019 Aug;78(8):1015–1018.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D, Miossec P. The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019 2019/12/01;15(12):747–757.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Sharif K, Sherlock J, et al. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev. 2020;294(1):27–47.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl2):ii49–ii54.
   PubMedGoogle Scholar
• D’Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21–28.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976–986.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014 Jan;73(1):48–55.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase iii study (SPIRIT-P1). J Rheumatol. 2018;45(3):367–377.
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct;64(10):3156–3167.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550–1558.
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018 Dec;5(2):567–582.
   PubMed Web of Science ®Google Scholar
• Tremfya (guselkumab) [package insert]. Janssen Biotech I, editor. Horsham. PA2017.
   Google Scholar
• Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol. 2019 2019/12/01/;139(12):2437–2446.e1.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Calderon C, Marciniak SJ Jr., et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016 Nov;72(11):1303–1310.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115–1125.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126–1136.
   PubMed Web of Science ®Google Scholar
• McGonagle DMI, Deodhar A, Schett G, et al. Effects of guselkumab, a monoclonal antibody that specifically binds to the p19-subunit of interleukin-23, on dactylitis and enthesitis in patients with active psoriatic arthritis: pooled results through week 24 from two phase 3 studies [abstract]. In: Arthritis Rheumatology. 2020. p. 72.
   Google Scholar
• Mease PJ, Gladman DD, Deodhar A, et al. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open. 2020;6(2):e001217.
   PubMed Web of Science ®Google Scholar
• Feld J, Chandran V, Haroon N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018 Jun;14(6):363–371.
   PubMed Web of Science ®Google Scholar
• Mease PHP, Gladman D, Poddubnyy D, et al. Efficacy of guselkumab, a monoclonal antibody that specifically binds to the p19 subunit of il-23, on axial-related endpoints in patients with active psa with imaging-confirmed sacroiliitis: week-52 results from two phase 3, randomized, double-blind, placebo-controlled studies [abstract]. In Arthritis Rheumatology. 2020.
   Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258–270.
   PubMed Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Banaszczyk K. Risankizumab in the treatment of psoriasis - literature review. Reumatologia. 2019;57(3):158–162.
   PubMedGoogle Scholar
• Mease PJ, Kellner H, Morita A, et al. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis. 2018;77(Suppl 2):200–201.
   Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Gabros SD, Pona A, et al. Tildrakizumab: a review of phase ii and iii clinical trials. Ann Pharmacother. 2019 Apr;53(4):413–418.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013 Apr;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015 May;122(5):939–948.
   PubMed Web of Science ®Google Scholar